NASDAQ:VBIV - VBI Vaccines Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.88 -0.05 (-1.71 %)
(As of 07/17/2018 07:36 AM ET)
Previous Close$2.93
Today's Range$2.80 - $2.96
52-Week Range$2.56 - $5.10
Volume137,199 shs
Average Volume462,161 shs
Market Capitalization$188.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
VBI Vaccines logoVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Debt-to-Equity Ratio0.11
Current Ratio3.77
Quick Ratio3.72

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$860,000.00
Price / Sales215.03
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book1.53

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-38,990,000.00
Net Margins-4,607.13%
Return on Equity-47.54%
Return on Assets-36.98%

Miscellaneous

Employees103
Outstanding Shares64,210,000
Market Cap$188.15

The Truth About Cryptocurrencies

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) posted its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.21 million. VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. View VBI Vaccines' Earnings History.

What price target have analysts set for VBIV?

3 brokers have issued 12 month price objectives for VBI Vaccines' stock. Their forecasts range from $10.00 to $13.00. On average, they expect VBI Vaccines' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 299.3% from the stock's current price. View Analyst Ratings for VBI Vaccines.

What is the consensus analysts' recommendation for VBI Vaccines?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of VBI Vaccines' key competitors?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 48)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 30)

Has VBI Vaccines been receiving favorable news coverage?

News articles about VBIV stock have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.20 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.60 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $2.88.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $188.15 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.